logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals ( IONS ) announced entering into a strategic collaboration agreement with AstraZeneca ( AZN ) to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of...

Read More

December 8, 2021

0

Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

Regenxbio in the NEWS  Regenxbio ( RGNX ) announced, on August 3, 2022, its intention to file a Biologics License Application ( BLA ) in 2024 using the FDA's accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type...

Read More

August 3, 2022

0

Gilead Sciences: A Promising Acquisition. See Also: Genmab and BioNTech: A Promising Expansion

Gilead Sciences to Acquire MiroBio At $405 Million Gilead Sciences ( GILD ) and MiroBio - a privately held U.K based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that they entered into a...

Read More

August 5, 2022

0

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

CRISPR, Intellia and Editas, Our Gene-Editing Sisters, are Rallying The three CRISPR gene-editing firms that we have chosen are enjoying rallies.  CRISPR Therapeutics ( CRSP ) and Intellia Therapeutics ( NTLA ) stocks’ rallying were the first to move products...

Read More

December 10, 2020

0

Acquisitions that Make Sense

Acquisitions  AstraZeneca Acquires Alexion Pharmaceuticals AstraZeneca ( AZN )  and Alexion Pharmaceuticals ( ALXN ) entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares ( ADSs )...

Read More

December 14, 2020

0

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

Intellia Therapeutics in the News Intellia Therapeutics ( NTLA ) presented the first demonstration of physiological protein levels of human alpha-1 antitrypsin ( AAT ) in non-human primates (NHPs) following a single administration.  Intellia Therapeutics Liver Gene Insertion Technology Intellia’s...

Read More

December 15, 2020

0

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals' Product AMX0035 for ALS  

On September 7th the FDA Will Review Amylyx Pharmaceuticals NDA for ALS Treatment Amylyx Pharmaceuticals ( AMLX ) announced that the U.S. FDA Peripheral and Central Nervous System Advisory Committee ( PCNSDAC ) will reconvene to review the New Drug...

Read More

August 11, 2022

0

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

Rhythm Pharmaceuticals Announces Successful Phase 3 Trial Results for Obesity In November 2020, when the U.S. FDA granted approval to the Rhythm Pharmaceuticals ( RYTM ) product IMCIVREE™ (setmelanotide) for obesity due to proopiomelanocortin ( POMC ), proprotein convertase subtilisin/Kexin...

Read More

December 29, 2020

0

Important Data Will Be Presented by Regenxbio on August 30th

Regenxbio to Present Important Data  Regenxbio ( RGNX ) will present important material at the Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place in Germany from August 30 through September 2, 2022. The presentations are...

Read More

August 23, 2022

0

Fate Therapeutics: Improving on Cellular Therapies

Fate Therapeutics: Developing Next Generation Cellular Therapies Fate Therapeutics ( FATE ) is a clinical-stage biopharmaceutical company developing first-in-class improved cellular immunotherapies for cancer. Fate Therapeutics uses its proprietary induced pluripotent stem cell ( iPSC ) product platform in clinical development...

Read More

August 25, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 35
  • 36
  • 37
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy